Prevention of Increasing Rates of Treatment Failure by Combining Sulfadoxine-Pyrimethamine with Artesunate or Amodiaquine for the Sequential Treatment of Malaria

Journal of Infectious Diseases

Volumn 188, Issue 8, 2003, Pages 1231-1238

  Dorsey, Grant ^a,c   Vlahos, Jonathan ^a   Kamya, Moses R ^b   Staedke, Sarah G ^a   Rosenthal, Philip J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MAKERERE UNIVERSITY MEDICAL SCHOOL   (Uganda)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE; ARTESUNATE; FANSIDAR; PLACEBO;

ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE MUTATION; HUMAN; INFANT; LIFESPAN; MAJOR CLINICAL STUDY; MALARIA; MALE; PARASITOSIS; PRESCHOOL CHILD; PREVALENCE; PRIORITY JOURNAL; RELAPSE; SURVIVAL; TREATMENT FAILURE; UGANDA; VIRUS INFECTION;

AMODIAQUINE; ANIMALS; ANTIMALARIALS; ARTEMISININS; CHILD, PRESCHOOL; DIHYDROPTEROATE SYNTHASE; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; HUMANS; INFANT; MALARIA, FALCIPARUM; MUTATION; PLASMODIUM FALCIPARUM; PYRIMETHAMINE; SESQUITERPENES; SULFADOXINE; TETRAHYDROFOLATE DEHYDROGENASE; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0242269869     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/378523     Document Type: Article

References (30)

1. White NJ, Nosten F, Looareesuwan S, et al. Averting a malaria disaster. Lancet 1999; 353:1965-7.
2. Wongsrichanalai C, Pickard AL, Wernsdorfer WH, Meshnick SR. Epidemiology of drug-resistant malaria. Lancet Infect Dis 2002; 2:209-18.
3. Mberu EK, Mosobo MK, Nzila AM, Kokwaro GO, Sibley CH, Watkins WM. The changing in vitro susceptibility pattern to pyrimethamine/ sulfadoxine in Plasmodium falciparum field isolates from Kilifi, Kenya. Am J Trop Med Hyg 2000; 62:396-401.
4. Nosten F, Luxemburger C, ter Kuile FO, et al. Treatment of multidrug-resistant Plasmodium falciparum malaria with 3-day artesunate-mefloquine combination. J Infect Dis 1994; 170:971-7.
5. Adjuik M, Agnamey P, Babiker A, et al. Amodiaquine-artesunate versus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children: a randomised, multicentre trial. Lancet 2002; 359:1365-72.
6. Dorsey G, Njama D, Kamya MR, et al. Sulfadoxine/pyrimethamine alone or with amodiaquine or artesunate for treatment of uncomplicated malaria: a longitudinal randomised trial. Lancet 2002; 360:2031-8.
7. Staedke SG, Kamya MR, Dorsey G, et al. Amodiaquine, sulfadoxine/ pyrimethamine, and combination therapy for treatment of uncomplicated falciparum malaria in Kampala, Uganda: a randomised trial. Lancet 2001; 358:368-74.
8. von Seidlein L, Milligan P, Pinder M, et al. Efficacy of artesunate plus pyrimethamine-sulfadoxine for uncomplicated malaria in Gambian children: a double-blind, randomized, controlled trial. Lancet 2000; 355:352-7.
9. Price RN, Nosten F, Luxemburger C, et al. Effects of artemisinin derivatives on malaria transmissibility. Lancet 1996; 347:1654-8.
10. Price RN, Nosten F, Luxemburger C, et al. Artesunate/mefloquine treatment of multi-drug resistant falciparum malaria. Trans R Soc Trop Med Hyg 1997; 91:574-7.
11. Wongsrichanalai C, Thimasarn K, Sirichaisinthop J. Antimalarial drug combination policy: a caveat. Lancet 2000; 355:2245-7.
12. Bloland PB, Ettling M, Meek S. Combination therapy for malaria in Africa: hype or hope? Bull World Health Organ 2000; 78:1378-88.
13. Warrell DA, Molyneux ME, Beales PF. Severe and complicated malaria. World Health Organization, Division of Control of Tropical Diseases. Trans R Soc Trop Med Hyg 1990; 84:1-65.
14. World Health Organization. Assessment of therapeutic efficacy of antimalarial drugs for uncomplicated falciparum malaria in areas with intense transmission. Document WHO/MAL/96.1077. Geneva: World Health Organization, 1996.
15. Cattamanchi A, Kyabayinze D, Hubbard A, Rosenthal PJ, Dorsey G. Distinguishing recrudescence from reinfection in a longitudinal antimalarial drug efficacy study: comparison of results based on genotyping of MSP-1, MSP-2, and GLURP. Am J Trop Med Hyg 2003; 68:133-9.
16. Kublin JG, Dzinjalamala FK, Kamwendo DD, et al. Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. J Infect Dis 2002; 185:380-8.
17. Kyabayinze D, Cattamanchi A, Kamya MR, Rosenthal PJ, Dorsey G. Validation of a simplified method for using molecular markers to predict sulfadoxine-pyrimethamine treatment failure in African children with falciparum malaria. Am J Trop Med Hyg (in press).
18. Duraisingh MT, Curtis J, Warhurst DC. Plasmodium falciparum: detection of polymorphisms in the dihydrofolate reductase and dihydropteroate synthetase genes by PCR and restriction digestion. Exp Parasitol 1998; 89:1-8.
19. Plowe CV, Djimde A, Bouare M, Doumbo O, Wellems TE. Pyrimethamine and proguanil resistance-conferring mutations in Plasmodium falciparum dihydrofolate reductase: polymerase chain reaction methods for surveillance in Africa. Am J Trop Med Hyg 1995; 52:565-8.
20. Zeger SL, Liang KY, Albert PS. Models for longitudinal data: a generalized estimating equation approach. Biometrics 1988; 44:1049-60.
21. White N. The assessment of antimalarial drug efficacy. Trends Parasitol 2002; 18:458-64.
22. Basco LK, Ringwald P. Molecular epidemiology of malaria in Yaounde, Cameroon. VII. Analysis of recrudescence and reinfection in patients with uncomplicated falciparum malaria. Am J Trop Med Hyg 2000; 63: 215-21.
23. Trape JF. The public health impact of chloroquine resistance in Africa. Am J Trop Med Hyg 2001; 64:12-7.
24. Mutabingwa TK, Nzila AM, Mberu EK, et al. Chlorproguanil-dapsone for treatment of drug-resistant falciparum malaria in Tanzania. Lancet 2001; 358:1218-23.
25. Zucker JR, Lackritz EM, Ruebush TK 2nd, et al. Childhood mortality during and after hospitalization in western Kenya: effect of malaria treatment regimens. Am J Trop Med Hyg 1996; 55:655-60.
26. Druilhe P, Daubersies P, Patarapotikul J, et al. A primary malarial infection is composed of a very wide range of genetically diverse but related parasites. J Clin Invest 1998; 101:2008-16.
27. Meshnick SR, Taylor TE, Kamchonwongpaisan S. Artemisinin and the antimalarial endoperoxides: from herbal remedy to targeted chemotherapy. Microbiol Rev 1996; 60:301-15.
28. Ittarrat W, Pickard AL, Rattanasinganchan P, et al. Recrudescence in artesunate-treated patients with falciparum malaria is dependent of parasite burden not on parasite factors. Am J Trop Med Hyg 2003; 68:147-52.
29. Wendo C. African scientists discuss drug-resistant malaria. Lancet 2002; 359:770.
30. Amukoye E, Winstanley PA, Watkins WM, et al. Chlorproguanildapsone: effective treatment for uncomplicated falciparum malaria. Antimicrob Agents Chemother 1997; 41:2261-4.